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Edited by Vladimir SkulachevAbstract Oxidants are known to modulate cell proliferation
and apoptosis, and induce synthesis of growth factors that play
an important role in tumor growth and invasion. Antioxidant
enzymes and thiol proteins regulating cellular redox state
constitute the major cellular protection against oxidants. Con-
sequently, they are also associated both with carcinogenesis and
tumor progression. Superoxide dismutases, glutamate cysteine
ligase, catalase, thioredoxins and peroxiredoxins, which are the
most important of these enzymes, are expressed in lung
malignancies, and especially in pleural mesothelioma. This has
consequences not only for tumor behavior but also for resistance
of tumor cells to cytotoxic drugs and radiation.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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The lung is directly exposed to higher levels of oxygen than
most other tissues. The level of reactive oxygen species (ROS) in
the lung is further increased by cigarette smoke, inﬂammation,
pollutants, chemicals and carcinogens, that lead to DNA
damage also by a free radical related mechanism [1–3]. Oxi-
dants, imbalance between the cellular redox state and pul-
monary defense systems evidently play a role both in the* Corresponding author. Fax: +358-9-47176107.
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Abbreviations: AOE, antioxidant enzyme; CAT, catalase; CYTP450ox,
cytochrome P450 oxidase; CuZnSOD, copper–zinc superoxide
dismutase; ECSOD, extracellular superoxide dismutase; G-6-P-D,
glucose-6-phosphate dehydrogenase; cGCS, gamma glutamyl cysteinyl
synthetase; GPX, glutathione peroxidase; GR, glutathione reductase;
GRX, glutaredoxin; GS, glutathione synthase; GSH, reduced gluta-
thione; GSSG, oxidized glutathione; GST, glutathione-S-transferase;
GT, glutamyl transpeptidase; H2O2, hydrogen peroxide; HIF, hypox-
ia-inducible factor; HOBr, hypobromide; HOCl, hypochloride; OH,
hydroxyl radical; MITO, mitochondria; MMP, matrix methallopro-
teinase; MnSOD, manganese superoxide dismutase; MRP, multidrug
resistance protein; NADPHox, NADPH oxidase; NO, nitric oxide;
ONOO, peroxynitrite; O2 , superoxide radical; PRX, peroxiredoxin;
RNS, reactive nitrogen species; ROS, reactive oxygen species; RSS,
reactive sulphur species; SOD, superoxide dismutase; TGFb, trans-
forming growth factor beta; TRX, thioredoxin; VEGF, vascular
endothelial growth factor; XAO, xanthine oxidase
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Lung cancer that is highly associated with cigarette smoking is
the most common malignancy worldwide, and its incidence is
still increasing. Pleural mesothelioma is associated with asbes-
tos, potent generator of free radicals, in most of the cases.
Mesothelioma is uncommon, but also its incidence is increas-
ing, the peak of its epidemic is expected in 2020 [4]. A common
feature in both these malignancies is their poor prognosis and
high resistance to chemotherapies and radiation.
There is clear evidence that free radicals are linked both to
carcinogenesis and tumor behavior. Most important reactive
metabolites also in human lung include superoxide radical (O2 ),
hydrogen peroxide (H2O2), hydroxyl radical (OH
), and a
number of reactive nitrogen and sulphur species (RNS, RSS)
(peroxynitrite, oxidized states of sulfur) which are generated by
multiple enzymatic reactions including NADPH oxidase
(NADPHox), peroxidases and inducible nitric oxide (NO) syn-
thase (Fig. 1). One major hypothesis explaining the importance
of oxidants and imbalance of the cellular redox state in lung
carcinogenesis is altered pro-oxidant intracellular environment
that facilitates mutations and/or inactivation of tumor sup-
pression genes and activates oncogenes with consequent chan-
ges in cell growth, survival and apoptosis [3,5,6]. Cellular redox
state regulates several pathways closely associated with cell
growth and survival including cMyc-, p53- [7–10], FAS-medi-
ated apoptosis and ras-mediated epidermal factor receptor-
dependent angiogenesis [11–13]. ROS induce CKIp21 (Cip1), a
gene causing permanent growth arrest/senescence and inacti-
vate PTEN, a tumor suppressor protein causing cell death and
senescence [14,15]. Degradation of hypoxia-inducible factor
(HIF) that is strongly associated with angiogenesis is regulated
by prolyl hydroxylases and asparagine hydroxylases also by a
oxygen-dependent mechanism [16–18] (Fig. 2). Thus oxidants
and cellular redox state are important determinants regulating
cell growth, survival and expression of tumor suppressor genes.2. Major antioxidant and thiol-disulﬁde regulating pathways in
mammalian cells and human lung
Normal human lung is eﬃciently protected and ‘‘buﬀered’’
against exogenous free radicals. Besides classical antioxi-
dant enzymes (AOEs), epithelial lining ﬂuid contains small
molecular weight antioxidants and proteins including a tri-
peptide glutathione (reduced glutathione, GSH) [19], mucinblished by Elsevier B.V. All rights reserved.
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Fig. 1. Generation of ROS and RNS with consequent eﬀects on ma-
lignant conversion. MITO, mitochondria; NADPHox, NADPH oxi-
dase; XAO, xanthine oxidase; CYTP450ox, cytochrome P450 oxidase;
O2 , superoxide radical; H2O2, hydogen peroxide; NO, nitric oxide;
ONOO, peroxynitrite; OH, hydroxyl radical; HOCl, hypochloride;
HOBr, hypobromide.
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ferrin, ferritin, ceruloplasmin, lactoferrin) and lipid (vitamin E)
and water (vitamin C) soluble vitamins [22]. Furthermore,
AOEs and related proteins have a highly compartmentalized
localization being also expressed in all cell organelles (like
mitochondria) and extracellularly.
Major human AOEs include superoxide dismutases (SODs),
catalase (CAT), enzymes associated with GSH metabolism and
its synthesis such as glutathione peroxidases (GPX) and glu-
tamate cysteine ligase (gamma glutamyl cysteinyl synthetase,
cGCS). There are three SODs, all of which are expressed also
in human lung. Manganese SOD (MnSOD) is mitochondrial,
CuZnSOD cytosolic and extracellular, ECSOD mainly extra-
cellular [22–24]. The decomposition of H2O2 occurs by GSH-OXIDANT STRE
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Fig. 2. Eﬀects of oxidant stress on the stabilization of HIF with increased
growth factors such as transforming growth factor beta (TGFbÞ and increase
tumor suppressor genes (e.g., p53 and PTEN).dependent enzymes and catalase which are located in the cy-
tosolic compartment and peroxisomes (Fig. 3). Among these
mechanisms GSH (glutamate–cysteine–glycine) is abundatly
localized to the epithelial lining ﬂuid of human lung [19] and its
reaction pathways are tightly linked to the reactions of other
thiol-containing proteins, that participate not only in scav-
enging of H2O2 but also to the regulation of the redox balance
of the cells.
In addition to the classical AOEs, human lung expresses
several thiol-containing proteins suggested to be major con-
tributors to the redox environment of the cells. These proteins
contain thiol-groups such as amino acid cysteine in their active
centers including the families of thioredoxins (TRX1 and
TRX2), thioredoxin reductases (TRR1 and TRR2), peroxire-
doxins (PRXs I–VI) and glutaredoxins (GRXI, GRX2) [25,26].
Their cell speciﬁc expression in human lung is located mainly
to alveolar macrophages, bronchial epithelial cells and alveolar
epithelium, critical areas in the oxidant protection of human
lung [27–30]. Besides these classical AOEs and the proteins of
TRX, PRX and GRX families, other detoxiﬁcation and oxi-
dant-induced gene products may play a signiﬁcant role in the
primary defense of human lung. Glutathione-S-transferases
(GSTs) belong to a group of detoxiﬁcation enzymes that also
require intracellular thiol tripeptide GSH for their catalytic
activity as is also the case with the multidrug resistance pro-
teins (MRPs) in the transport of various drugs from the cells.
Both GSTs and MRPs have earlier been extensively investi-
gated and reviewed [31–39]. Overall, human lung has a highly
specialized antioxidative and redox-modulatory machinery
that is expressed in the airways and functions as a major reg-
ulator of the cellular redox state both in non-malignant and
malignant cells and their surroundings.
2.1. Superoxide dismutases and catalase in lung and pleural
malignancies
Among the classical AOEs, MnSOD has been most widely
investigated in malignant cells. In vitro studies and experi-SS
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Fig. 3. Major antioxidant enzymes and related pathways in human tissues. CuZnSOD, copper–zinc superoxide dismutase; MnSOD, manganese
SOD; ECSOD, extracellular SOD; CAT, catalase; GPX, glutathione peroxidase; GR, glutathione reductase; GSH, reduced glutathione; GSSG,
oxidized glutathione; GST, glutathione-S-transferase; MRP, multidrug resistance protein; G-6-P-D, glucose-6-phosphate dehydrogensase; cGT,
gamma glutamyl transpeptidase; cGCS, gamma glutamyl cysteinyl synthetase (glutamate cysteine ligase); GS, glutathione synthase; GPXe, extra-
cellular glutathione peroxidase.
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by transfection decreases the growth, proliferation, and inva-
sion of cultured malignant cells and may decrease tumor
growth in experimental animal models in vivo [40–45]. Most
these studies have introduced one enzyme such as MnSOD to
the cells. This type of manipulation leads to disturbance of the
natural oxidant/antioxidant balance of the cell, and therefore,
does not reﬂect the situation in vivo. The results may thus be
incorrectly interpreted if they are directly extrapolated to hu-
man studies The ﬁnal and net eﬀect of MnSOD is most likely
related to the redox-milieu of the cells, which has been found
to be related to the balance of MnSOD and some H2O2
scavenging enzymes in the cells [46].
MnSOD expression in normal lung and there in bronchial
epithelium, alveolar epithelium and alveolar macrophages is
low [47–49]. The promoter of MnSOD contains binding sites
for a number of transcription factors reviewed by Zelko et al.
[50], which explains the high inducibility of MnSOD both by
cytokines, radiation and cytotoxic drugs [47,50–52] and its
downregulation [53,54]. There is clear evidence that functional
MnSOD polymorphism is associated with the development of
lung cancer and possibly pleural mesothelioma, and also that
MnSOD may be altered in precancerous tissues such as in
dysplatic bronchial epithelium [55–58]. In contrast what one
might expect from in vitro studies, several invasive and resis-
tant tumors show high MnSOD levels or activities including
brain tumors and various gastrointestinal malignancies [59–
64]. However, no consistent results on the MnSOD expression
in lung cancer have been reported [65–68], but a large study
recently showed signiﬁcantly elevated levels of MnSOD also in
lung cancer [68]. More consistenly MnSOD (the mRNA,protein and/or activity) is highly elevated in malignant pleural
mesothelioma, a tumor with poor prognosis and high resis-
tance to chemotherapies and radiation [69–72]. Mesothelioma
cells with highest (10-fold) MnSOD activity also possess ele-
vated resistance to oxidants such as menadione and to cyto-
toxic drugs such as epirubicin [69], and cell lines expressing
high MnSOD show decreased apoptosis [72]. Thus, malignant
pleural mesotheliomas contain highly elevated MnSOD in the
tumor cells with potential consequences to tumor behavior and
drug resistance.
CuZnSOD is a cytosolic relatively constitutive enzyme being
mainly expressed in bronchial epithelium [48]. A number of
CuZnSOD functional polymorphisms have been characterized
[57], but no associations have been shown between CuZnSOD
polymorphisms and development of lung diseases. CuZnSOD
contains several binding sites for transcription factors [73], but
it is not induced by cytokines or ROS to the same extent as
MnSOD in the lung [47,52] although it may be induced by
radiation and xenochemicals [74]. There are some studies
showing no dramatic changes of the messenger or protein
levels of CuZnSOD in lung malignancies [67,68], while as with
MnSOD, its overexpression has been reported in mesotheli-
oma cells [75].
The expression of ECSOD in the lung is high [76,77], but
very little is known about its signiﬁcance in any malignancy.
Functional polymorphic variant of ECSOD (that is rare, 3–6%
in various populations) decreases the anchoring of ECSOD to
negatively charged polysaccharides such as heparin in the ex-
tracellular matrix where this enzyme is mainly located [78].
There are, however, no studies on this polymorphism in
malignant lung diseases. Recent study has shown that the ex-
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the normal lung [79]. Since ECSOD is located in the extra-
cellular space, its low expression in lung cancer may have
fundamental importance in tumor invasion which is regulated
by the cellular redox state.
Catalase represents a H2O2 scavenging enzyme with optimal
activity at high H2O2 concentrations. In the lung, catalase is
localized mainly in alveolar macrophages and alveolar epi-
thelium [52]. This enzyme is relatively constitutive, no major
induction has been reported by cytokines or oxidants in the
lung. Catalase has not usually been connected to malignancies,
but its expression in mesothelioma is high [80] suggesting that
also this enzyme may be connected to highly resistant invasive
tumors. This phenomenon may also have clinical signiﬁcance
since inhibition of catalase in vitro by aminotriaxole has
shown to potentiate oxidant toxicity in mesothelioma cells
[81].
2.2. Thiol modulating proteins and human lung and pleural
malignancies
There is relatively good evidence that thiol related detoxiﬁ-
cation mechanisms such as GSTs and MRPs are closely as-
sociated with human lung malignancies and their resistance to
cytotoxic drugs [34–39]. Relatively little is, however, known
about the enzymes directly related to GSH synthesis and thiol-
containing redox modulator proteins TRXs, PRXs or GRXs
in malignant diseases. The rate limiting enzyme in GSH syn-
thesis is glutamate cysteine ligase (i.e., cGCS). It consists of
two subunits: a heavy subunit with catalytic function (cGCSh)
and a light subunit with a regulatory role (cGCSl). Both
subunits are expressed mainly in bronchial epithelium [82].
Especially the heavy subunit is induced by oxidants and oxi-
dant generating anticancer drugs, such as cisplatin and doxo-
rubicin, possibly by provoking oxidative stress in cancer cells
[83]. In the only reported study on cGCS-mRNA expression in
mesothelioma cell lines, also cGCSh-mRNA was co-ordinately
overexpressed with MRP and the expression correlated with
doxorubicin resistance [84]. Recent studies have also shown
that malignat mesothelioma represents a tumor with high ex-
pression of cGCSh; moreover depletion of GSH by inhibiting
cGCS both in mesothelioma and lung adenocarcinoma cells
potentiated oxidant and drug-induced cell damage in vitro
[81,85]. Overall there is strong evidence that GSH associated
mechanisms and especially cGCSh are highly upregulated in
malignant lung diseases and GSH depletion would be fa-
vourable for cell killing.
Thiol proteins TRX, TRR, PRX and GRX can be hypoth-
esized to have fundamental role both in carcinogenesis and
tumor progression. TRX is a 12 kDa multifunctional protein
catalyzing protein disulﬁde reductions in conjuction with
TRR. Besides being a powerful regulator of cellular redox
state, TRX increases cell proliferation and resistance of vari-
ous cells to oxidants and drugs [25,86]. The TRX system is also
induced at least by oxidant stress, tumor promoting agents and
cytotoxic drugs [26,50]. In agreement with these notions, TRX
mRNA was prominently expressed in mesothelioma cells [75]
and immunohistochemical studies conﬁrmed high expression
of TRX and/or TRR proteins both in malignant mesothelioma
and lung cancer [71,87]. Given the important role of this sys-
tem in the drug resistance, TRX may also increase the resis-
tance of lung carcinoma and mesothelioma to the cytotoxic
drugs and radiation.Peroxiredoxins constitute another thiol-containing antioxi-
dant family of proteins that have been recently detected from
human lung, and there mainly in bronchial epithelium, alve-
olar epithelium and alveolar macrophages [27]. PRXs are
closely associated with TRX-dependent reactions, being also
called as thioredoxin peroxidases. Normal healthy lung ap-
pears to express abundantly of nearly all these proteins. These
proteins are also stress-inducible being associated with cell
signalling pathways; they also participate in the cellular anti-
oxidant defense, at least part of them induce cell proliferation
and protect cells from undergoing apoptosis [88–90]. Most
proteins of the PRX family (PRX I, II, III, V, VI) are highly
expressed in malignant mesothelioma [29] and some of them
also in lung cancer [91]. GRX family of proteins is linked more
to GSH pathways, their role in lung malignancies is unknown.
It appears that PRXs represent a new family of redox modu-
latory thiol proteins with potential consequences on cell pro-
liferation, tumor growth and resistance.3. Conclusions
It is known that lung antioxidant levels are decreased in non-
malignant lung disorders such as in asthma and chronic ob-
structive lung disease [47,82], whereas the primary antioxidant
mechanisms are high, probably induced in lung malignancies,
and especially in malignant mesothelioma. In this disease high
antioxidant capacity of the tumor cells can be hypothesized to
lead to the observed high resistance to cytotoxic drugs and
radiation. Even more importantly recently characterized fam-
ilies of thiol proteins may prove to have fundamental role in
cancer biology, cellular redox state being one of the major
modulators of a number of growth factors associated with
angiogenesis and cell proliferation. These thiol proteins such as
TRXs and PRXs not only increase cell survival and prolifer-
ation but also protect both non-malignant and malignant cells
against oxidants, radiation and chemotherapies. However, the
functional signiﬁcance of these thiol proteins is still unresolved
and waits future studies.
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